Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Integration of digital pathology and AI tools

Digital pathology partnership to streamline workflows and enhance diagnostics

Digital pathology software company Fujifilm Healthcare Europe and Ibex Medical Analytics, specializing in AI-powered cancer diagnostics, announce a formal partnership to support efficient and…

News • NHS rollout

Liquid biopsy: new ‘blood test-first’ approach for lung cancer

A new ‘liquid biopsy’ test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, while helping avoid further tests and treatments including chemotherapy.

Article • San Antonio Breast Cancer Symposium (SABCS)

Young women and breast cancer: research in focus

At the San Antonio Breast Cancer Symposium (SABCS), three experts presented new approaches and study results for the treatment of breast cancer in young women.